Search Results - "Yamagishi, Sho-ichi"

Molecular Insights for Precision Care in Cardiovascular Disease: Perspectives from the Special Issue.

Authors: Terasaki, Michishige Yamagishi, Sho-ichi

Source: International Journal of Molecular Sciences. Jan2026, Vol. 27 Issue 1, p493. 4p.

Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation.

Authors: Yamagishi, Sho-ichi¹ shoichi@med.kurume-u.ac.jp

Source: Cardiovascular Diabetology. 1/28/2019, Vol. 18 Issue 1, p1-4. 4p. 1 Diagram.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Protective role of sulphoraphane against vascular complications in diabetes.

Authors: Yamagishi, Sho-Ichi Matsui, Takanori

Source: Pharmaceutical Biology. Oct2016, Vol. 54 Issue 10, p2329-2339. 11p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Carnitine deficiency is associated with late-onset hypogonadism and depression in uremic men with hemodialysis.

Authors: Fukami, Kei Yamagishi, Sho-ichi Sakai, Kazuko et al.

Source: Aging Male. Dec2014, Vol. 17 Issue 4, p238-242. 5p.

Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients.

Authors: Fukami, Kei Yamagishi, Sho-ichi Sakai, Kazuko et al.

Source: Clinical Kidney Journal. Oct2014, Vol. 7 Issue 5, p470-474. 5p.

This result is not displayed to guests.
Login for full access.

Involvement of Iron-Evoked Oxidative Stress in Smoking-Related Endothelial Dysfunction in Healthy Young Men.

Authors: Fukami, Kei Yamagishi, Sho-ichi Iida, Shuji et al.

Source: PLoS ONE. Feb2014, Vol. 9 Issue 2, p1-6. 6p.

Serum Levels of Advanced Glycation End Products (AGEs) are Inversely Associated with the Number and Migratory Activity of Circulating Endothelial Progenitor Cells in Apparently Healthy Subjects.

Authors: Ueda, So Yamagishi, Sho-ichi Matsui, Takanori et al.

Source: Cardiovascular Therapeutics. Aug2012, Vol. 30 Issue 4, p249-254. 6p.

Serum Levels of Advanced Glycation End Products (AGEs) are Independent Correlates of Insulin Resistance in Nondiabetic Subjects.

Authors: Tahara, Nobuhiro Yamagishi, Sho-ichi Matsui, Takanori et al.

Source: Cardiovascular Therapeutics. Feb2012, Vol. 30 Issue 1, p42-48. 7p.

Involvement of Toxic AGEs (TAGE) in the Pathogenesis of Diabetic Vascular Complications and Alzheimer's Disease.

Authors: Takeuchi, Masayoshi Yamagishi, Sho-ichi

Source: Journal of Alzheimer's Disease. 2009, Vol. 16 Issue 4, p845-858. 14p. 3 Diagrams.

Inhibitors of Advanced Glycation End Products (AGEs): Potential Utility for the Treatment of Cardiovascular Disease.

Authors: Yamagishi, Sho-ichi Nakamura, Kazuo Matsui, Takanori et al.

Source: Cardiovascular Therapeutics. Spring2008, Vol. 26 Issue 1, p50-58. 9p. 1 Chart.

Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects.

Authors: Tahara, Atsuko Tahara, Nobuhiro Yamagishi, Sho-ichi et al.

Source: International Journal of Food Sciences & Nutrition. Dec2017, Vol. 68 Issue 8, p1013-1020.

Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study.

Authors: Takahashi, Noriyuki Ohara, Makoto Yokoyama, Hiroki et al.

Source: Diabetes Therapy. May2026, p1-15. 15p.